Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

Title:Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

Volume: 15 Issue: 10

Author(s): Paul J. Gilligan

Affiliation:

Keywords: Kinase inhibitors, Leucine-rich repeat kinase 2 (LRRK2), Parkinson’s disease.

Abstract: Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have been linked to several familial and sporadic late-onset cases of Parkinson’s disease. The cumulative data for the effects of mutant forms of this enzyme on neuronal degradation and the pathophysiology of Parkinson’s disease create a compelling case for drug discovery based on inhibition of the mutant forms of LRRK2. This review focuses on structure-activity relationships for inhibitors of LRRK2 and the data supporting a potential role of these agents in treating Parkinson’s disease.

Cite this article as:

Gilligan J. Paul, Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease, Current Topics in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/156802661510150328223655